Novartis AG (NVS)
101.30
+1.08
(+1.08%)
USD |
NYSE |
May 10, 10:13
Novartis Accounts Receivable (Quarterly): 7.84B for March 31, 2024
Accounts Receivable (Quarterly) Chart
Historical Accounts Receivable (Quarterly) Data
Date | Value |
---|---|
March 31, 2024 | 7.84B |
December 31, 2023 | 7.107B |
September 30, 2023 | 6.819B |
June 30, 2023 | 9.195B |
March 31, 2023 | 8.916B |
December 31, 2022 | 8.066B |
September 30, 2022 | 8.422B |
June 30, 2022 | 8.643B |
March 31, 2022 | 8.409B |
December 31, 2021 | 8.005B |
September 30, 2021 | 8.377B |
June 30, 2021 | 8.40B |
March 31, 2021 | 8.265B |
December 31, 2020 | 8.217B |
September 30, 2020 | 8.073B |
June 30, 2020 | 7.644B |
March 31, 2020 | 8.541B |
December 31, 2019 | 8.301B |
September 30, 2019 | 7.826B |
June 30, 2019 | 7.973B |
March 31, 2019 | 7.612B |
December 31, 2018 | 8.727B |
September 30, 2018 | 8.585B |
June 30, 2018 | 8.803B |
March 31, 2018 | 8.918B |
Date | Value |
---|---|
December 31, 2017 | 8.60B |
September 30, 2017 | 8.482B |
June 30, 2017 | 8.38B |
March 31, 2017 | 8.234B |
December 31, 2016 | 8.202B |
September 30, 2016 | 8.547B |
June 30, 2016 | 8.606B |
March 31, 2016 | 8.464B |
December 31, 2015 | 8.18B |
September 30, 2015 | 8.495B |
June 30, 2015 | 8.75B |
March 31, 2015 | 8.794B |
December 31, 2014 | 8.275B |
September 30, 2014 | 8.857B |
June 30, 2014 | 9.371B |
March 31, 2014 | 10.32B |
December 31, 2013 | 9.902B |
September 30, 2013 | 10.50B |
June 30, 2013 | 10.79B |
March 31, 2013 | 10.48B |
December 31, 2012 | 10.05B |
September 30, 2012 | 10.52B |
June 30, 2012 | 10.49B |
March 31, 2012 | 10.60B |
December 31, 2011 | 10.32B |
Accounts Receivable Definition
Account used to record sales made "on account", meaning that the company has made a sale but has not collected payment. When company collects cash as payment, the corresponding account receivable is decreased.
Accounts Receivable (Quarterly) Range, Past 5 Years
6.819B
Minimum
Sep 2023
9.195B
Maximum
Jun 2023
8.152B
Average
8.241B
Median
Accounts Receivable (Quarterly) Benchmarks
Roche Holding AG | 13.85B |
Sandoz Group AG | -- |
Amgen Inc | 6.776B |
Incyte Corp | 745.53M |
MorphoSys AG | 35.48M |